JP2014530010A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530010A5
JP2014530010A5 JP2014533316A JP2014533316A JP2014530010A5 JP 2014530010 A5 JP2014530010 A5 JP 2014530010A5 JP 2014533316 A JP2014533316 A JP 2014533316A JP 2014533316 A JP2014533316 A JP 2014533316A JP 2014530010 A5 JP2014530010 A5 JP 2014530010A5
Authority
JP
Japan
Prior art keywords
rsv
protein
arginine
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014533316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530010A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014530010A publication Critical patent/JP2014530010A/ja
Publication of JP2014530010A5 publication Critical patent/JP2014530010A5/ja
Pending legal-status Critical Current

Links

JP2014533316A 2011-09-30 2012-09-27 呼吸器合胞体ウイルス用の組み換えナノ粒子rsvfワクチン Pending JP2014530010A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201161542040P 2011-09-30 2011-09-30
US61/542,040 2011-09-30
US201161542721P 2011-10-03 2011-10-03
US61/542,721 2011-10-03
US201261611834P 2012-03-16 2012-03-16
US61/611,834 2012-03-16
US201261614286P 2012-03-22 2012-03-22
US61/614,286 2012-03-22

Publications (2)

Publication Number Publication Date
JP2014530010A JP2014530010A (ja) 2014-11-17
JP2014530010A5 true JP2014530010A5 (https=) 2016-09-29

Family

ID=47996397

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014533316A Pending JP2014530010A (ja) 2011-09-30 2012-09-27 呼吸器合胞体ウイルス用の組み換えナノ粒子rsvfワクチン

Country Status (14)

Country Link
US (4) US20130122032A1 (https=)
EP (1) EP2760469A4 (https=)
JP (1) JP2014530010A (https=)
KR (1) KR20140077169A (https=)
CN (2) CN104080476A (https=)
AU (1) AU2013201495B2 (https=)
BR (1) BR112014007616A2 (https=)
CA (1) CA2849471A1 (https=)
HK (1) HK1222125A1 (https=)
IL (1) IL231637A0 (https=)
MX (1) MX2014003777A (https=)
RU (1) RU2014117068A (https=)
SG (2) SG10201602434UA (https=)
WO (1) WO2013049342A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
JP5813513B2 (ja) 2008-12-09 2015-11-17 ノババックス,インコーポレイテッド 修飾rsvfタンパク質及びその使用方法
CA2909077A1 (en) * 2013-04-08 2014-10-16 Stacie Lynn Lambert Vaccine composition and method of use
US20150110825A1 (en) * 2013-09-24 2015-04-23 Massachusetts Institute Of Technology Self-assembled nanoparticle vaccines
CN105087643A (zh) * 2014-04-16 2015-11-25 中国科学院上海巴斯德研究所 重组表达人呼吸道合胞病毒f1蛋白胞外区的方法及表达系统
US10100372B2 (en) 2014-06-18 2018-10-16 Georgia State University Research Foundation, Inc. Recombinant RSV reporter virus
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
CA2996762A1 (en) 2015-08-31 2017-03-09 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
US10538557B2 (en) * 2015-09-02 2020-01-21 Janssen Vaccines & Prevention B.V. Stabilized viral class I fusion proteins
EP4494650A3 (en) * 2015-09-03 2025-03-26 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
CN106547635B (zh) 2015-09-18 2020-10-09 阿里巴巴集团控股有限公司 一种作业的操作重试方法和装置
EP3393512B1 (en) 2015-12-23 2025-11-19 Pfizer Inc. Rsv f protein mutants
PH12022552125A1 (en) * 2016-04-05 2023-04-12 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
CN106124767A (zh) * 2016-05-12 2016-11-16 广州瑞辉生物科技股份有限公司 呼吸道合胞病毒IgA抗体检测试纸条及其检测方法
CN110352072A (zh) * 2016-10-03 2019-10-18 马萨诸塞大学 用于免疫免疫前受试者以抵抗呼吸道合胞病毒(rsv)的方法
SG11201908376UA (en) * 2017-03-15 2019-10-30 Novavax Inc Methods and compositions for inducing immune responses against clostridium difficile
KR102774312B1 (ko) 2017-04-04 2025-03-05 유니버시티 오브 워싱톤 파라믹소바이러스 및/또는 뉴모바이러스 f 단백질을 표시하는 자가-조립 단백질 나노구조체 및 이의 용도
CN107050446B (zh) * 2017-04-19 2020-08-11 武汉博沃生物科技有限公司 经修饰的季节流感-rsv联合疫苗及其制备方法
WO2019023196A1 (en) 2017-07-24 2019-01-31 Novavax, Inc. METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE
WO2019063844A1 (en) * 2017-09-29 2019-04-04 Universiteit Antwerpen VACCINATION AGAINST SYNCYTIAL RESPIRATORY VIRUS
CA3095216A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
EP3768308A4 (en) 2018-03-19 2022-01-26 Novavax, Inc. MULTIVALENT INFLUENZA NANOPARTICLE VACCINES
WO2020076141A1 (ko) * 2018-10-12 2020-04-16 에스케이바이오사이언스 주식회사 재조합 rsv 생백신주 및 이의 제조 방법
US12370252B2 (en) 2018-10-29 2025-07-29 Emory University RSV virus-like particles and methods of use thereof
KR102725189B1 (ko) * 2018-11-01 2024-10-31 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
AU2020227545B2 (en) * 2019-02-28 2023-10-19 Km Biologics Co., Ltd. RSV F/G chimeric vaccine
CN110229219B (zh) * 2019-06-21 2021-03-30 中国科学院武汉病毒研究所 一种新型的呼吸道合胞病毒疫苗抗原的制备方法及其用途
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CA3165371A1 (en) * 2020-01-27 2021-08-05 Gale Smith Coronavirus vaccine formulations
WO2021198413A1 (en) * 2020-04-02 2021-10-07 Janssen Vaccines & Prevention B.V. Stabilized vaccine compositions
KR102721070B1 (ko) * 2020-11-27 2024-10-24 한국과학기술연구원 Rsvf를 발현하는 엑소좀 및 이의 용도
CN113855796B (zh) * 2021-07-30 2024-01-26 河北医科大学 卡介苗作为呼吸道合胞病毒灭活疫苗佐剂的应用
CN118434756A (zh) * 2021-11-19 2024-08-02 达冕生物有限公司 核糖核酸呼吸道合胞病毒(rsv)疫苗的组合物和方法
KR102785012B1 (ko) * 2021-12-14 2025-03-20 경희대학교 산학협력단 Rsv 항원 단백질을 포함하는 바이러스 유사입자 및 이를 이용한 백신
WO2024050015A1 (en) * 2022-09-01 2024-03-07 Novavax, Inc. Downstream process for purification of viral proteins with hydrophobic membrane domain for use in vaccine compositions
CN117986382B (zh) * 2022-11-04 2025-04-01 北京康乐卫士生物技术股份有限公司 针对rsv的重组亚单位疫苗及其应用
WO2024259624A1 (en) * 2023-06-21 2024-12-26 Shenzhen Genius Biotech Service Co. Ltd A modified rsv f protein, a nanoparticle, a composition and a vaccine against respiratory syncytial virus infection
AU2024314167A1 (en) * 2023-06-21 2026-02-05 Shenzhen Shenxin Biotechnology Co., Ltd. Respiratory syncytial virus (rsv) vaccine
WO2025026448A1 (zh) * 2023-08-03 2025-02-06 广州穗和生物技术有限公司 修饰的呼吸道合胞病毒f蛋白及其用途
WO2025051250A1 (zh) * 2023-09-07 2025-03-13 北京科兴中维生物技术有限公司 呼吸道合胞病毒f蛋白及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027825A2 (en) * 2003-04-25 2005-03-31 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
JP2010522540A (ja) * 2007-03-21 2010-07-08 アイディー バイオメディカル コーポレイション オブ ケベック キメラ抗原
HUE025702T2 (en) * 2007-07-19 2016-04-28 Novavax Inc Avian Flu Chimeric VLPs
PL2222710T3 (pl) * 2007-12-24 2017-01-31 Id Biomedical Corporation Of Quebec Rekombinowane antygeny rsv
JP2011514337A (ja) * 2008-02-25 2011-05-06 ノババックス,インコーポレイテッド 糖ガラス化ウィルス様粒子(vlp)
KR101027159B1 (ko) * 2008-07-28 2011-04-05 뮤추얼아이피서비스(주) 타겟 영상 검출 장치 및 그 방법
WO2010077712A1 (en) * 2008-12-09 2010-07-08 Novavax, Inc. Bovine respiratory syncytial virus virus-like particle (vlps)
JP5813513B2 (ja) * 2008-12-09 2015-11-17 ノババックス,インコーポレイテッド 修飾rsvfタンパク質及びその使用方法

Similar Documents

Publication Publication Date Title
JP2014530010A5 (https=)
RU2014117068A (ru) Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса
Liang et al. Adjuvants for coronavirus vaccines
Fougeroux et al. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity
JP6957580B2 (ja) 新規多価ナノ粒子に基づくワクチン
Boyoglu-Barnum et al. Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice
Elkashif et al. Adenoviral vector‐based platforms for developing effective vaccines to combat respiratory viral infections
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
Haynes Progress and challenges in RSV prophylaxis and vaccine development
Stepanova et al. Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes
JP2022533318A (ja) 気道感染の治療または予防のためのサブユニットワクチン
JP2015509707A5 (https=)
JP2014502156A5 (https=)
RU2011128371A (ru) Модифицированные f протеины sv и способы их применения
JP2015536134A5 (https=)
JP2016510983A5 (https=)
HRP20240996T1 (hr) Prefuzija rsv f proteina i njihova uporaba
CN106659777A (zh) 免疫原性组合产品
JP2016510983A (ja) 呼吸器合胞体ウイルスの熱安定な融合前fタンパク質オリゴマーおよび免疫組成物におけるその使用
JP2015517489A5 (https=)
JP2015524422A5 (https=)
JP2013517783A5 (https=)
JP2011528222A5 (https=)
Kotomina et al. Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease
JP2015500827A5 (https=)